TABLE 1.
ORR at different cut-off points in durvalumab-treated patients.
| Cut-off point | ORR, % (95% CI) PD-L1–high |
ORR, % (95% CI) PD-L1–low/negative |
|---|---|---|
| TC1% | 14.5 (9.2–21.3) | 8.8 (1.9–23.7) |
| TC10% | 15.7 (9.7–23.4) | 8.6 (2.9–19.0) |
| TC25% | 16.1 (9.8–24.2) | 9.0 (3.4–18.5) |
| TC50% | 16.7 (8.9–27.3) | 11.2 (5.9–18.8) |
| IC1% | 16.2 (10.3–23.6) | 6.1 (1.3–16.9) |
| IC10% | 15.8 (9.1–24.7) | 10.7 (5.0–19.4) |
| IC25% | 17.1 (7.2–32.1) | 12.3 (7.3–19.0) |
| T50%/IC25% | 17.2 (10.3–26.1) | 8.8 (3.6–17.2) |
Abbreviations: CI, confidence interval; IC, immune cell; ORR, objective response rate; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; TC, tumor cell.